This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

In Q1 Public Biopharmas Shift Fundraising Into Overdrive

ATLANTA, April 8, 2013 /PRNewswire-USNewswire/ -- Biotech companies generated $5 billion in the first quarter of 2013, just 3% less than the $5.15 billion raised in the first quarter last year. The heavy lifting for the period was carried out by public companies, which were responsible for 65% of the total, according to BioWorld Today, the daily biopharmaceutical news source.

(Logo: http://photos.prnewswire.com/prnh/20120628/DC32901LOGO )

The $3.25 billion raised by these public companies was 33% higher than the $2.5 billion total raised in the same period of 2012. The amount included almost $3 billion in follow-on financings with public companies seizing the opportunity in a favorable investor climate to sell shares at or near their prevailing market value with little to no price discount.

It has been a great quarter for public biotech companies as the sector continued to remain hot with investors, according to Peter Winter, editor of BioWorld Insight, the analytical companion to BioWorld Today. Large biotech companies, with market caps greater than $1 billion, collectively saw their share prices jump by an average of 21.5% in the first quarter.

That performance almost doubled the Dow Jones Industrial average, which hit a new historical high and closed the quarter up 11.25%.

"A steady flow of positive news from elite biotech companies, including product approvals and strong financial reports, have kept investors engaged. The sector's momentum, which started early last year, shows no signs of slowing down," said Winter.

There is already some evidence that this is starting to happen with the Nasdaq Biotechnology Index (NBI), which includes a broad range of large and smaller companies, jumping 16% in the first quarter. The performance of NBI was also mirrored by the BioWorld Stock Report, which recorded an average share price change for the 231 public biotechnology companies tracked by the report at 15.6%.

Editor's note: This is an excerpt from today's top BioWorld story. Read the complete article here: https://www.bioworld.com/

BioWorld Today, and its analytical companion, BioWorld Insight, are the biopharmaceutical industry's most respected news sources and have been for more than two decades. All of that information is now leveraged in BioWorld Data, business intelligence for biopharmaceutical executives. Call for details (800) 477-6307.

Contact: Lynn Yoffee404-262-5408 www.bioworld.com

SOURCE BioWorld

Copyright 2011 PR Newswire. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 18,080.14 +21.45 0.12%
S&P 500 2,117.69 +4.76 0.23%
NASDAQ 5,092.0850 +36.0220 0.71%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs